Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of IMP4297 maintenance after first-line platinum chemotherapy in advanced ovarian cancer
CTR20192330Phase 3Active
- Sponsor
- IMPACT Therapeutics
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of senaparib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by IMPACT Therapeutics. Started Dec 2019; status: active.
02
Drugs
senaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20192330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192330.